SCHEMBL2865817

SCHEMBL2865817

O=C(NCCN1CCc2ccccc2C1)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 1/20 0.47
ATM Q13315 1/20 0.47
TSHR P16473 2/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 1/20 0.40
PRMT5 O14744 2/20 0.40
WDR77 Q9BQA1 2/20 0.40
CYP2D6 P10635 2/20 0.40
MAPT P10636 2/20 0.40
OPRM1 P35372 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862082 0.87 HTR4 (0.43) TSHRCYP1A2POLB
SCHEMBL2868696 0.87 SIGMAR1 (0.44) TSHRMEN1KMT2ACYP2D6CYP2C9
SCHEMBL2858188 0.86 L3MBTL1 (0.44) ALDH1A1HPGDTSHRMEN1ALOX15
SCHEMBL2863108 0.86 L3MBTL1 (0.44) ALDH1A1HPGDTSHRMEN1ALOX15
SCHEMBL2869035 0.85 SMN1; SMN2 (0.43) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL2861377 0.85 NPSR1 (0.38) ALDH1A1SMN1; SMN2MEN1KMT2ACYP2D6
SCHEMBL2864346 0.84 HTT (0.39) HTTKMT2ACYP2D6CYP1A2
SCHEMBL2867140 0.83 NPSR1 (0.37)
SCHEMBL2856576 0.83 NPSR1 (0.37) SMN1; SMN2MEN1KMT2ACYP2D6CYP2C9
SCHEMBL2864640 0.82 NPSR1 (0.38) HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 ALDH1A1 2926/4885HTT 3138/4885HPGD 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.